Luminopia Inc, a digital health company developing a new class of treatments for neuro-visual disorders, announced on Thursday that it has been named a Winner at the 2026 Digital Health Hub – Digital Health & AI Awards, presented by the Digital Health Hub Foundation at HLTH USA 2026 in Las Vegas.
Luminopia won in the Best-in-Class track within the Therapeutics, Pharmacy & Medication Innovation category. Luminopia said this recognition highlights the company's commitment to its mission of treating neuro-visual conditions and its continued efforts to advance healthcare through innovative technologies and solutions.
The Digital Health Hub – Digital Health & AI Awards aim to celebrate organizations developing solutions that address some of healthcare's most pressing challenges, improve patient outcomes, and drive meaningful change across the healthcare ecosystem.
Luminopia's recognition follows clinical and commercial momentum for its FDA-cleared prescription digital therapeutic for amblyopia, the leading cause of vision loss in children. To date, Luminopia has been prescribed to over 15,000 patients by more than 1,600 providers across the country.
US FDA clears Medtronic plc's Hugo robotic-assisted surgery system for general surgery
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Apotex launches generic version of INLYTA in US market
Genentech secures first FDA approval for primary membranous nephropathy treatment
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme